Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Clinical Research and Equipment Industry Analysis

UpdatedAug 04, 2026
DataAggregated Company Financials
Companies22
  • 7D9.4%
  • 3M19.5%
  • 1Y17.1%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 9.4%, with Divi's Laboratories up 13%. During this same period, the OneSource Specialty Pharma underperformed, falling 12%. This takes the industry's 12 month performance to a gain of 17%. Earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 05 Aug 2026₹3.9t₹370.3b₹49.2b40x78.5x10.4x
Fri, 03 Jul 2026₹3.3t₹361.8b₹46.4b41.6x71.5x9.2x
Sun, 31 May 2026₹3.3t₹362.1b₹46.1b31.4x70.8x9x
Tue, 28 Apr 2026₹3.2t₹350.2b₹46.2b31x68.5x9x
Thu, 26 Mar 2026₹2.9t₹350.2b₹46.2b29.4x61.7x8.1x
Sat, 21 Feb 2026₹2.9t₹350.2b₹46.2b28.1x63.6x8.4x
Mon, 19 Jan 2026₹3.0t₹342.6b₹48.4b31x62.4x8.8x
Wed, 17 Dec 2025₹3.1t₹342.6b₹48.4b32.1x63.7x9x
Fri, 14 Nov 2025₹3.2t₹338.7b₹48.0b47.3x66.3x9.4x
Sun, 12 Oct 2025₹3.3t₹331.4b₹45.5b44.2x71.5x9.8x
Tue, 09 Sep 2025₹3.2t₹331.4b₹45.5b51x69.4x9.5x
Thu, 07 Aug 2025₹3.1t₹321.5b₹42.2b52.5x74.2x9.7x
Sat, 05 Jul 2025₹2.9t₹300.8b₹37.2b45.3x79.2x9.8x
Mon, 02 Jun 2025₹2.9t₹300.0b₹37.2b46.5x76.6x9.5x
Wed, 30 Apr 2025₹2.6t₹288.4b₹30.7b46.8x85.1x9.1x
Fri, 28 Mar 2025₹2.6t₹287.4b₹30.8b44.8x83.9x9x
Sun, 23 Feb 2025₹2.5t₹287.4b₹30.8b48.9x81.2x8.7x
Tue, 21 Jan 2025₹2.5t₹269.1b₹30.1b50.1x84.7x9.5x
Thu, 19 Dec 2024₹2.5t₹269.1b₹30.1b51.6x83.5x9.3x
Sat, 16 Nov 2024₹2.3t₹254.1b₹28.8b47.8x80.5x9.1x
Mon, 14 Oct 2024₹2.5t₹247.6b₹26.3b50.7x93.7x9.9x
Wed, 11 Sep 2024₹2.3t₹247.6b₹26.3b52x87.8x9.3x
Fri, 09 Aug 2024₹1.9t₹205.8b₹24.7b36.9x78x9.3x
Sun, 07 Jul 2024₹1.8t₹202.0b₹23.9b37x75.6x9x
Tue, 04 Jun 2024₹1.7t₹195.1b₹21.6b32.1x76.5x8.5x
Thu, 02 May 2024₹1.5t₹167.8b₹18.7b30.7x79.1x8.8x
Sat, 30 Mar 2024₹1.3t₹168.5b₹18.6b27.4x71.2x7.9x
Mon, 26 Feb 2024₹1.4t₹168.5b₹18.6b31.5x75.9x8.4x
Wed, 24 Jan 2024₹1.4t₹165.9b₹18.9b30.8x72.5x8.2x
Fri, 22 Dec 2023₹1.3t₹155.9b₹18.1b21x73.6x8.5x
Sun, 19 Nov 2023₹1.3t₹156.5b₹18.1b22.1x74.2x8.6x
Tue, 17 Oct 2023₹1.4t₹154.7b₹19.7b25.7x70.9x9x
Thu, 14 Sep 2023₹1.4t₹154.7b₹19.7b25.9x72.3x9.2x
Sat, 12 Aug 2023₹1.4t₹160.2b₹23.3b22.8x59.6x8.7x
Price to Earnings Ratio

59.6x


Total Market Cap: ₹1.4tTotal Earnings: ₹23.3bTotal Revenue: ₹160.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Clinical Research and Equipment Industry Price to Earnings3Y Average 74.7x202420252026
Current Industry PE
  • Investors are optimistic on the Indian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 78.5x which is higher than its 3-year average PE of 74.7x.
  • The 3-year average PS ratio of 9.0x is lower than the industry's current PS ratio of 10.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 28% per year over the last three years.
  • Revenues for these companies have grown 32% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Indian Clinical Research and Equipment compare with similar industries?

IN Market2.24%
Healthcare1.41%
Life Sciences9.43%
Clinical Research and Equipment9.43%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹8.38k12.8%
+₹253.0b		30.7%PE76x
ANTHEM Anthem Biosciences₹819.254.5%
+₹19.9b		11.2%PE80.1x
SAILIFE Sai Life Sciences₹1.37k5.1%
+₹14.0b		71.9%PE83.1x
INDGN Indegene₹553.758.9%
+₹10.9b		-2.6%PE33.3x
530239 Suven Life Sciences₹310.305.5%
+₹4.2b		15.6%PS1150.2x

Latest News

544184
₹145.80
Borosil Scientific
7D
-5.0%
1Y
-6.0%
DIVISLAB
₹8,378.00
Divi's Laboratories
7D
12.8%
1Y
30.7%
Analysis Article • 23h

Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...
530239
₹310.30
Suven Life Sciences
7D
5.5%
1Y
15.6%
INDGN
₹553.75
Indegene
7D
8.9%
1Y
-2.6%
Analysis Article • Aug 03

Indegene Limited (NSE:INDGN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

It's been a good week for Indegene Limited ( NSE:INDGN ) shareholders, because the company has just released its latest...
ONESOURCE
₹1,530.60
OneSource Specialty Pharma
7D
-11.6%
1Y
-19.3%
Analysis Article • Jul 29

Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results

It's been a good week for OneSource Specialty Pharma Limited ( NSE:ONESOURCE ) shareholders, because the company has...
ANTHEM
₹819.25
Anthem Biosciences
7D
4.5%
1Y
11.2%
New Narrative • Jul 28

Capacity Expansion And Modalities Shift Will Support Stronger Long-Term Earnings Visibility

Catalysts About Anthem Biosciences Anthem Biosciences is a contract research, development and manufacturing organization with a large focus on CRDMO services and specialty ingredients across small molecules, peptides, fermentation and related modalities. What are the underlying business or industry changes driving this perspective?
540729
₹24.03
Vanta Bioscience
7D
-5.0%
1Y
-5.9%
524394
₹641.20
Vimta Labs
7D
6.4%
1Y
-2.8%
BROOKS
₹60.79
Brooks Laboratories
7D
-3.1%
1Y
-61.5%
511509
₹21.54
Vivo Bio Tech
7D
-4.7%
1Y
-33.4%
INFLUX
₹287.50
Influx Healthtech
7D
-0.9%
1Y
86.7%
539267
₹11.29
Samsrita Labs
7D
-1.8%
1Y
-55.8%
AKUMS
₹667.40
Akums Drugs and Pharmaceuticals
7D
0.8%
1Y
32.9%
Narrative Update • Jul 03

AKUMS: Upcoming Board Actions And Dividends Will Support Future Earnings Expansion

Analysts have lifted the fair value estimate for Akums Drugs and Pharmaceuticals from ₹646.67 to ₹730.00, citing updated assumptions around revenue growth, profit margins, a slightly altered discount rate, and future P/E. What’s in the News for Akums Drugs and Pharmaceuticals A board meeting is scheduled on May 14, 2026 to consider and approve the quarter and full year results for the period ended March 31, 2026, and to consider dividend recommendations, the appointment of Mahajan & Aibara LLP as Internal Auditors for FY 2026-27, and other matters.
DCAL
₹188.24
Dishman Carbogen Amcis
7D
3.4%
1Y
-24.6%
SAILIFE
₹1,366.40
Sai Life Sciences
7D
5.1%
1Y
71.9%
INNOVACAP
₹941.95
Innova Captab
7D
-1.6%
1Y
3.3%
Narrative Update • Jun 26

INNOVACAP: Higher Fair Value And Governance Moves Will Support Bullish Re Rating

Analysts have revised their price target for Innova Captab to ₹1,078.50 from ₹891.50, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key inputs to the new valuation view. What’s in the News for Innova Captab The board has scheduled a meeting on May 25, 2026, to consider the reappointment of M/s.